Better Therapeutics- Tradeable Rights - March 2021 Overview

Better Therapeutics- Tradeable Rights - March 2021 Research & Development

Research & Development expenses for MCADR.

Quarterly R&D Expenses

$1.83M

↓ 66.53% YoY

As of Sep 30, 2023

Annual R&D Expenses (TTM)

$10.51M

↓ 46.77% YoY

Trailing 12 months ending Sep 30, 2023

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin